RxDoctor Payments Data

Tiffany Langston

Family · Greenville, NCNPI 1588607634

Payments from drug & device makers

$1,540in general payments, 2019–2025

Across 30 payments — averaging $51.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Preventric Diagnostics, Inc.$649
  • Abbott$324
  • GSK$125
  • AbbVie$121
  • Boston Scientific$120
  • Exact Sciences$43
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$1,540100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Preventric Diagnostics, Inc.2$649
Abbott9$324
GSK1$125
AbbVie1$121
Boston Scientific4$120
Exact Sciences3$43
Phadia US Inc.2$33
Dynavax Technologies Corporation2$30
Novo Nordisk2$28
The Binding Site Inc.1$19
Tactile Systems Technology Inc1$19
Pfizer1$16
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,540 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,182
Medicare patients
131
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$64,384
EliquisApixaban57$37,539
MounjaroTirzepatide21$22,444
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,478
VraylarCariprazine Hcl12$16,350
JanuviaSitagliptin Phosphate18$15,484
RybelsusSemaglutide12$14,517
MyrbetriqMirabegron26$11,301
Breo ElliptaFluticasone/Vilanterol24$9,906
XareltoRivaroxaban13$7,413
LinzessLinaclotide12$6,532
Doxepin Hcl12$3,261
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,781
Rosuvastatin Calcium200$2,768
Omeprazole136$1,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$37,53957 claims
GSKTrelegy Ellipta, Breo Ellipta$125$29,38454 claims
AbbVieVraylar, Linzess$121$22,88224 claims
MerckJanuvia$14$15,48418 claims
Novo NordiskRybelsus$28$14,51712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.

Other family in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →